Monika Tornsen
Director/Board Member bei IMMUNIC, INC.
Profil
Monika Maria Tornsen is an Independent Director at Immunic, Inc. and President-North America at Calliditas Therapeutics AB.
She was previously Senior Vice President & General Manager-US at Sarepta Therapeutics, Inc., Vice President-Global Therapeutic at Genzyme Corp., and Chief Commercial Officer at Passage Bio, Inc. Tornsen is a graduate of the University of Lund.
Aktive Positionen von Monika Tornsen
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMUNIC, INC. | Director/Board Member | 05.07.2022 |
| CALLIDITAS THERAPEUTICS AB | Corporate Officer/Principal | 07.01.2024 |
Ehemalige bekannte Positionen von Monika Tornsen
| Unternehmen | Position | Ende |
|---|---|---|
| PASSAGE BIO, INC. | Corporate Officer/Principal | 01.12.2022 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2021 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.01.2019 |
Ausbildung von Monika Tornsen
| University of Lund | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| CALLIDITAS THERAPEUTICS AB | Health Technology |
| PASSAGE BIO, INC. | Health Technology |
| IMMUNIC, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
